EN
EN
About TCRCure
Research and Development
Product and Cinical trial
News and Media
Recruitment
Patient-first cell therapy innovation
 
HomeNews and MediaIndustry Trends
Industry Trends
Expert opinions：Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D ligand system
  • 0










 


  • Pre：--
  • Next：--
11.12
2021
Source：
Keysword：
Related Reading

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
Contact Us
About TCRCure
Research and Development
Product and Cinical trial
News and Media
Recruitment

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer